Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Medicenna Therapeutics (MDNAF) reported a narrower fiscal second-quarter net loss while warning that additional financing is required to sustain operations. For the quarter ended September 30, 2026, net loss was $4.0 million, or $0.04 per share, versus $4.9 million, or $0.06 per share, a year earlier. Cash fell to $3.7 million from $5.7 million at June 30, 2026, and is insufficient for planned operations over the next twelve months.
MDNA11's Phase 1/2 ABILITY-1 trial completed enrollment of 152 patients. Among 20 evaluable biomarker-selected gastrointestinal cancer patients, the response rate was 40% and disease control rate was 80%; five of eight responses were confirmed. Bizaxofusp produced median survival of 13.7 months versus 6.2 months in an external control among high-dose, confirmed IDH-wildtype patients. Medicenna plans regulatory discussions for MDNA11 and is pursuing partnerships for bizaxofusp and MDNA209.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointQuarterly net loss narrowed to $4.0 million, or $0.04 per share, versus $4.9 million, or $0.06, a year earlier.
- Moderate pointMDNA11 Phase 1/2 ABILITY-1 completed enrollment of 152 patients in November 2026.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Medicenna is pursuing partnership opportunities to advance bizaxofusp into a planned pivotal Phase 3 study.
- Minor pointQuarterly research and development expenses fell to $3.1 million from $4.1 million a year earlier.
- Minor pointQuarterly general and administrative expenses fell to $1.0 million from $1.4 million a year earlier.
18 minor points
- Minor pointMDNA11 with or without pembrolizumab achieved 40% response and 80% disease control in 20 evaluable biomarker-selected gastrointestinal cancer patients.
- Minor pointGastrointestinal cohort responses remained ongoing at data cut-off; median response duration had not been reached.
- Minor pointMDNA11 monotherapy produced regression in all eight measurable hepatic target lesions across four evaluable MSI-H gastrointestinal cancer patients.
- Minor pointSecondary checkpoint-inhibitor-resistant melanoma patients receiving MDNA11 alone had 30% response in a 10-patient expansion cohort.
- Minor pointPrimary checkpoint-inhibitor-resistant melanoma patients receiving MDNA11 plus pembrolizumab had 38% response in an eight-patient expansion cohort.
- Minor pointMDNA11 plus pembrolizumab achieved 28.6% confirmed response (2/7) in secondary checkpoint-inhibitor-resistant MSS endometrial cancer.
- Minor pointMDNA11 showed no dose-limiting toxicities through 120 µg/kg; over 90% of treatment-related adverse events were Grade 1–2.
- Minor pointMDNA11 had no Grade 5 treatment-related adverse events reported.
- Minor point. Forward-looking: it has not happened yet and may not happen.Medicenna plans regulatory discussions on a potential registrational path for MDNA11 in checkpoint-inhibitor-resistant MSI-H/TMB-H gastrointestinal cancers.
- Minor point. Forward-looking: it has not happened yet and may not happen.Medicenna plans continued evaluation of MDNA11 development opportunities in checkpoint-inhibitor-resistant melanoma.
- Minor pointRandomized Phase 1b NEO-CYT continues evaluating MDNA11 combinations before surgery in high-risk, surgically resectable melanoma.
- Minor pointBizaxofusp median survival was 13.7 versus 6.2 months against a propensity score-balanced external control in 19 high-dose, confirmed IDH-wildtype patients.
- Minor pointBizaxofusp survival also favored treatment in broader confirmed IDH-wildtype and full per-protocol populations, with hazard ratios of 0.625 and 0.621.
- Minor pointPreclinical MDNA209 studies showed CD122 blockade and greater IL-2 pathway potency than antibody comparators in human T-cell assays.
- Minor pointMDNA209 suppressed IL-2/IL-15-driven immune-cell activation and expansion while preserving regulatory T-cell viability over four days.
- Minor pointMDNA209 extended median survival to 23.5 and 26 days versus 7 days in two acute graft-versus-host disease mouse models.
- Minor pointMedicenna is evaluating MDNA209 for autoimmune and inflammatory diseases and pursuing potential partnerships.
- Minor point. Forward-looking: it has not happened yet and may not happen.MDNA113 planning targets an IND submission and first-in-human Phase 1 study in 2027.
Negative
- Major pointExisting cash is insufficient for planned operations over the next twelve months; additional financing is required.
- Minor pointCash and cash equivalents declined to $3.7 million at September 30, 2026, from $5.7 million at June 30.
- Minor point. Forward-looking: it has not happened yet and may not happen.Failure to secure sufficient funding could require further expenditure reductions or development deferrals.
- Minor pointLiquidity measures included workforce reductions, reduced external consultant spending and prioritization of development activities.
- Minor pointOnly five of eight gastrointestinal cancer responses were confirmed at the data cut-off.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MDNA11 Phase 1/2 ABILITY-1 completes 152-patient enrollment and demonstrates
The melanoma data were similarly encouraging, with ORRs of
Bizaxofusp Phase 2b analysis showed median overall survival (mOS) of 13.7 months versus 6.2 months for a propensity score-balanced external control in IDH-wildtype recurrent glioblastoma (rGBM) patients treated with a high dose of bizaxofusp (≥180 µg total dose)
MDNA209 demonstrated potent CD122 blockade and extended median survival by approximately 3- to 4-fold in aggressive preclinical models of acute graft-versus-host disease
TORONTO and HOUSTON, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines™ for cancer and autoimmune diseases, today reported financial results and corporate highlights for the fiscal quarter ended September 30, 2026, together with recent developments across its pipeline.
"Since the end of our second quarter, Medicenna has delivered a series of important clinical and preclinical readouts across MDNA11, bizaxofusp and MDNA209," said Fahar Merchant, PhD, President and Chief Executive Officer of Medicenna. "ABILITY-1 is now fully enrolled, and the Society for Immunotherapy of Cancer 2026 Annual Meeting (SITC) results provide compelling evidence of durable activity with MDNA11 in heavily pretreated gastrointestinal cancers, including patients whose disease had progressed on prior checkpoint therapy and patients with active liver metastases. The melanoma data were similarly encouraging, with ORRs of
PROGRAM AND BUSINESS UPDATE
Highlights for the three months ended September 30, 2026, together with certain recent developments, include:
MDNA11: Long-Acting Beta-Enhanced IL-2 Superkine for Solid Tumors
- Phase 1/2 ABILITY-1 enrollment completed. In November 2026, Medicenna announced completion of enrollment in the global Phase 1/2 ABILITY-1 study. A total of 152 patients from Canada, the United States, Australia, Europe and South Korea were enrolled to evaluate MDNA11 as monotherapy and in combination with pembrolizumab in advanced solid tumors.
- Encouraging SITC 2026 gastrointestinal cancer data. Among 20 efficacy-evaluable patients with protocol-defined MSI-H or MSS TMB-H gastrointestinal cancers, MDNA11 ± pembrolizumab achieved a
40% objective response rate (8/20) and an80% disease control rate (16/20). Five of eight responses were confirmed, median duration of response had not been reached, and responses were ongoing at the data cut-off. The cohort was heavily pretreated, with a median of three prior systemic treatments;65% had received prior immune checkpoint inhibitor therapy and35% had active liver metastases at baseline. - Notable single-agent activity in liver metastases. All four evaluable patients with MSI-H gastrointestinal cancers and measurable hepatic target lesions treated with MDNA11 monotherapy experienced regression of their hepatic target lesions, with regression observed across all eight measurable hepatic target lesions (8/8) in patients with pancreatic ductal adenocarcinoma, colorectal cancer, and cholangiocarcinoma.
- Activity in ICI-resistant melanoma and endometrial cancer. In protocol-defined Stage IV cutaneous melanoma expansion cohorts, ORR was
30% in patients with secondary ICI resistance treated with MDNA11 monotherapy (n=10) and38% in patients with primary ICI resistance treated with MDNA11 + pembrolizumab (n=8). In MSS endometrial cancer with secondary ICI resistance, MDNA11 + pembrolizumab achieved a confirmed ORR of28.6% (2/7). - Manageable safety profile. No dose-limiting toxicities were observed through 120 µg/kg. More than
90% of treatment-related adverse events were Grade 1 or Grade 2 and predominantly transient, and no Grade 5 treatment-related adverse events were reported. - Advancing development strategy. The Company plans to pursue regulatory discussions regarding a potential registrational development path for MDNA11 in ICI-resistant MSI-H/TMB-H gastrointestinal cancers and to continue evaluating development opportunities in ICI-resistant melanoma.
- Ongoing phase 1b NEO-CYT. The randomized Phase 1b NEO-CYT study continues to evaluate MDNA11 in combination with nivolumab ± ipilimumab prior to surgery in patients with high-risk, surgically resectable melanoma.
Bizaxofusp (formerly MDNA55): Empowered IL-4 Superkine for rGBM
- New Phase 2b survival results presented at SNO 2026. In the confirmed IDH-wildtype population receiving at least 180 µg (N=19), mOS was 13.7 months versus 6.2 months for the propensity score-balanced external control arm (HR 0.499; p=0.013).
- Survival benefit across broader populations. Survival also favored bizaxofusp in the broader confirmed IDH-wildtype (N=37; HR 0.625) and full per-protocol (N=44; HR 0.621) populations.
- Partnership strategy. Medicenna continues to pursue partnership opportunities to advance bizaxofusp into the planned pivotal Phase 3 study.
MDNA209: CD122 Superantagonist for Autoimmune and Inflammatory Diseases
- Potent CD122 blockade. October 2026 preclinical data showed that MDNA209 potently blocks CD122-mediated IL-2 and IL-15 signaling, including greater IL-2 pathway potency than antibody comparators in human T-cell assays.
- Suppression of disease-driving immune activity. In human immune-cell studies, MDNA209 suppressed IL-2/IL-15-driven activation and expansion while preserving regulatory T-cell viability over four days.
- Extended survival in autoimmune disease models. In two aggressive acute GvHD mouse models, long-acting MDNA209 extended median survival to 23.5 and 26 days versus 7 days in controls.
- Development and partnering. Medicenna is evaluating MDNA209 for autoimmune and inflammatory diseases and pursuing potential partnership opportunities.
MDNA113: Targeted Anti-PD-1 x IL-2 Bifunctional Superkine
- Continuing IND-enabling development. MDNA113 is a targeted, conditionally activated anti-PD-1 x IL-2 bifunctional Superkine. AACR 2026 preclinical data supported differentiated dosing and safety, including doses up to 50 mg/kg in non-human primates.
Planning is underway for an IND submission and first-in-human Phase 1 study in 2027.
QUARTERLY FINANCIAL RESULTS
Medicenna ended the quarter on September 30, 2026, with cash and cash equivalents of
For the three months ended September 30, 2026, the Company reported total operating costs of
Net loss for the quarter was
Research and development expenses were
General and administrative expenses were
Liquidity and Capital Resources
The Company continues to actively manage its liquidity and has implemented cost reduction initiatives, including workforce reductions, reduced spending on external consultants and the prioritization of clinical and preclinical development activities. These measures are intended to preserve capital while advancing key development milestones.
The Company's existing cash resources are insufficient to fund its planned operations over the next twelve months, and additional financing will be required to sustain operations. Medicenna continues to evaluate potential sources of capital, including equity financings, strategic partnerships, licensing arrangements and other non-dilutive financing opportunities.
There can be no assurance that additional financing or strategic transactions will be completed on acceptable terms or within the required timeframe. If sufficient additional funding is not secured, the Company may be required to further reduce or defer planned expenditures and development activities and/or to undertake other adjustments that the Company determines to be necessary or advisable.
Medicenna's financial statements for the three and six months ended September 30, 2026 and the related management's discussion and analysis (MD&A) are available under Medicenna's issuer profile on SEDAR+ at www.sedarplus.ca.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer and autoimmune diseases. Medicenna's lead immuno-oncology program, MDNA11, is a long-acting IL-2 Superkine designed to selectively activate cancer-fighting immune cells; enrollment has been completed in the Phase 1/2 ABILITY-1 study and MDNA11 is also being evaluated in the Phase 1b NEO-CYT study. The Company is developing MDNA113, a targeted PD-1 x IL-2 bifunctional immunotherapy for solid tumors, and MDNA209, an IL-2/IL-15 superantagonist designed to block the CD122 pathway in autoimmune and inflammatory diseases, using its proprietary BiSKIT and T-MASK platforms. The Company's most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
For more information, visit www.medicenna.com, and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding the continued clinical development and potential therapeutic benefits of MDNA11; potential regulatory interactions and registrational development strategies for MDNA11, including in ICI-resistant MSI-H/TMB-H gastrointestinal cancers and melanoma; the continued enrollment and development of the NEO-CYT study; the proposed pivotal Phase 3 development strategy, partnership activities and potential therapeutic benefits of bizaxofusp; the continued preclinical development, potential therapeutic applications and partnership opportunities for MDNA209; the timing and advancement of an IND submission and first-in-human study for MDNA113; the Company's financing plans, cash runway and ability to execute its planned expenditures and other initiatives (including, in each case, the timing thereof); and the Company's future operations, plans, objectives and expectations. Forward-looking statements are subject to risks and uncertainties, and actual results and future events could differ materially from those anticipated. Important factors that could cause actual results to differ materially from the Company's expectations include clinical-development, regulatory, financing and partnership risks, the risk that clinical or preclinical results may not be replicated in later-stage studies, and the risks detailed in the Company's latest annual information form and other filings with applicable securities regulators.
The reader is cautioned that assumptions used in the preparation of forward-looking information may prove to be incorrect. Actual results may differ materially from those predicted as a result of known and unknown risks, uncertainties and other factors. Readers should not place undue reliance on forward-looking information. Forward-looking statements are made as of the date hereof and, except as required by law, the Company does not intend and does not assume any obligation to update or revise them.
This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this news release.
Investor and Company Contact
Daniel Scarr
Director, Corporate Development
Medicenna Therapeutics
ir@medicenna.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much cash does Medicenna have, and does it need more financing?
Medicenna had $3.7 million in cash and cash equivalents at September 30, 2026, insufficient to fund planned operations over the next twelve months. Additional financing is required to sustain operations. Potential capital sources under evaluation include equity financing, partnerships, licensing and other non-dilutive financing opportunities.
What did Medicenna's MDNA11 trial show in gastrointestinal cancers?
MDNA11 with or without pembrolizumab achieved a 40% objective response rate (8/20) and an 80% disease control rate (16/20) among evaluable patients with protocol-defined MSI-H or MSS TMB-H gastrointestinal cancers. Five responses were confirmed, responses were ongoing at data cut-off, and median response duration had not been reached.